Savara Inc Lease Obligation Incurred
Savara Inc (SVRA) reported Lease Obligation Incurred of $40.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-03-06.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2017-03-06
- Savara Inc lease obligation incurred for the quarter ending 2015-12-31 was $5.00K.
- Savara Inc lease obligation incurred for the quarter ending 2015-03-31 was $33.00K.
- Savara Inc lease obligation incurred for fiscal 2015 was $40.00K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|
| 2015-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $40.00K 10-K · filed 2017-03-06 | |
| 2015-09-30 | $35.00K 10-Q · filed 2016-11-08 | ||
| 2015-03-31 | $33.00K 10-Q · filed 2016-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |